Clay B Siegall bought $1.2M of IMNM
President and CEO at Immunome Inc.. 150,000 shares at an average of $7.75, traded Jan 31, 2025, filed Feb 3, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.2M at market
- +6Relative to holdingsHoldings up 29%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-002824, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2025 | POpen-market purchase Common Stock | +150,000 | $7.75 | $1.2M | 669,636 | Feb 3, 2025 |
Related signals
Other insiders at Immunome Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Immunome Inc. | Jack Higgins Chief Scientific Officer | $334k 13,200 shares | -17% | |
| 37Weak | IMNMbuy Immunome Inc. | Jean Jacques Bienaime director | $47k 5,000 shares | +16% | |
| 48Moderate | Immunome Inc. | Jean Jacques Bienaime director | $61k 7,800 shares | +33% | |
| 76Notable | Immunome Inc. | Clay B Siegall President and CEO | $999k 137,100 shares | +20% | |
| 43Moderate | Immunome Inc. | Jean Jacques Bienaime director | $57k 7,000 shares | +42% | |
| 50Moderate | Immunome Inc. | Philip Tsai Chief Technology Officer | $104k 12,300 shares | +59% | |
| 50Moderate | Immunome Inc. | Philip Tsai Chief Technology Officer | $198k 21,000 shares | - | |
| 49Moderate | Immunome Inc. | Robert Lechleider Chief Medical Officer | $150k 15,805 shares | - | |
| 70Notable | Immunome Inc. | Clay B Siegall President and CEO | $962k 100,000 shares | +24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.